Kidney Week

Abstract: FR-PO1124

Association Between Urine Sediment Examination and Adverse Outcomes in Hospitalized Patients with AKI and Severe COVID-19

Session Information

• COVID-19 - II
  November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

• 000 Coronavirus (COVID-19)

Authors

• Vasquez Vasquez, Julio Alberto, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Julio Alberto Vasquez Vasquez,

• Martinez-Sanchez, Froylan David, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Froylan David Martinez-Sanchez,

• Bastida Castro, Luis Angel, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Luis Angel Bastida Castro,

• Diaz-Jarquin, Alejandra, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Alejandra Diaz-Jarquin,

• Vargas-Sánchez, Laura Viviana, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Laura Viviana Vargas-Sánchez,

• Flores Perez, Fidel Ivan, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Fidel Ivan Flores Perez,

• Medina Garza, Omhariany, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Omhariany Medina Garza,

• Meza Hernández, Javier Andrés, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Javier Andrés Meza Hernández,

• Zarza, Victor Manuel Paz, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Victor Manuel Paz Zarza,

• Moreno-Novales, Rafael, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Rafael Moreno-Novales,

• García, Juan Carlos González, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Juan Carlos González García,

• Salinas-Ramirez, Mauricio Adrian, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Mauricio Adrian Salinas-Ramirez,

• Juarez, Joana Balderas, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Joana Balderas Juarez,

• Tenorio-Aguirre, Erika Karina, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico

Erika Karina Tenorio-Aguirre,

Background

COVID-19 and Acute kidney injury (AKI) are associated with increased mortality and worse kidney outcomes. Although several factors including age, sex, and comorbidities are associated with increased morbimortality, to our knowledge, no study has dwelled into the evaluation of urine sediment and prognosis in patients who developed AKI during Covid-19.

Methods

Retrospective cohort study that included clinical and biochemical data of 288 hospitalized patients with COVID-19 who developed AKI at any stage. Univariate and Cox regression analyses were used to evaluate the role of urine sediment and progression in AKI with Covid-9. Mayor Adverse Kidney Events (MAKE) was a composite of AKI stage 3, mortality, and need for renal replacement therapy. The Perazella score was used to evaluate the number of cellular renal tubular epithelial cells (CRTEC) and granular casts.

Results

The mean age of the patients was 57 ± 14 years, 69% were women, the mean body mass index (BMI) was 27.9±5.6 kg/m2, and median time in hospital was 11 (6-19) days. Overall, 47.3% had diabetes and 33.8% hypertension. The rate of AKI 3, MAKE, and mortality was 32.3%, 46.3% and 32.6%, respectively. After adjusting for demographics and comorbidities the Cox model regression, a Perazella score 2 and 3 was associated with increased risk for AKI 3 (HR= 2.664 [1.174-6.645] and HR= 3.273 [1.172-9.139]; respectively), MAKE (HR= 3.162 [1.486-6.727] and HR= 4.644 [1.815-11.886]; respectively), and mortality (HR= 3.322 [1.375-8.251] and HR= 4.743 [1.594-14.112]; respectively).

Conclusion

The examination of the urine sediment could predict worse outcomes in patients with AKI and severe Covid-19.